Atlas Venture Life Science Advisors, LLC

CAMBRIDGE, MA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 10, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$631.2M2026 Q3
Positions9
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%

Atlas Venture Life Science Advisors, LLC reported 9 positions worth $631.2M as of September 30, 2026 (13F filed November 10, 2026). Largest holding: KYMR (50.4%).

9 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 KYMRKymera Therapeutics$318.3M50.43%2,847,541——+14.1%
▸ 2 IRONDisc Medicine$90.6M14.35%1,384,025——+22.2%
▸ 3 OBXObsidian Therapeutics$61.8M9.80%4,503,149———
▸ 4 KLRAKailera Therapeutics$59.1M9.36%5,171,282——+16.2%
▸ 5 DYNDyne Therapeutics$55.4M8.78%3,440,720——+6.5%
▸ 6 QTTBQ32 Bio$22.5M3.56%2,717,106——+5.3%
▸ 7 SIONSionna Therapeutics$15.8M2.50%2,995,602——-36.7%
▸ 8 KRROKorro Bio$7.7M1.21%773,260——+37.3%
▸ 9 ODTXOdyssey Therapeutics$59.8K0.01%2,692———

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Atlas Venture Life Science Advisors, LLC hold as of Q3 2026?

Atlas Venture Life Science Advisors, LLC reported 9 positions worth $631.2M in its Q3 2026 13F filing. Largest positions: KYMR (50.4%), IRON (14.4%), OBX (9.8%), KLRA (9.4%) and DYN (8.8%).

What did Atlas Venture Life Science Advisors, LLC buy in Q3 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Atlas Venture Life Science Advisors, LLC sell in Q3 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.